Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review
- PMID: 35019939
- DOI: 10.1001/jamadermatol.2021.5485
Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review
Abstract
Clinical question: What is the efficacy of interventions for cutaneous disease in systemic lupus erythematosus (SLE) in randomized clinical trials (RCTs)?
Bottom line: Available RCT evidence on the management of cutaneous disease in SLE is sparse and of limited quality. Among traditional options, methotrexate and hydroxychloroquine have the strongest evidence compared with placebo in the end points of complete clinical response and number of clinical flares, respectively, while chloroquine appears noninferior to methotrexate in achieving complete clinical response.
Comment on
-
Interventions for cutaneous disease in systemic lupus erythematosus.Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. Cochrane Database Syst Rev. 2021. PMID: 33687069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
